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Health care workers (HCW) are particularly at risk of acquiring tuberculosis (TB), even in countries with low TB incidence.
Therefore, TB screening in HCW is a useful prevention strategy in countries with both low and high TB incidence. Tuberculin
skin test (TST) is widely used although it suffers of low specificity; on the contrary, the in vitro enzyme immunoassay tests (IGRA)
show superior specificity and sensitivity but aremore expensive.The present study reports the results of a three-year TB surveillance
among HCW in a large teaching hospital in Rome, using TST (by standardMantoux technique) and IGRA (by QuantiFERON-TB)
as first- and second-level screening tests, respectively. Out of 2290 HCW enrolled, 141 (6.1%) had a positive TST; among them, 99
(70.2%) underwent the IGRA and 16 tested positive (16.1%).The frequency of HCW tested positive for TB seems not far from other
experiences in low incidence countries. Our results confirm the higher specificity of IGRA, but, due to its higher cost, TST can be
considered a good first level screening test, whose positive results should be further confirmed by IGRA before the patients undergo
X-ray diagnosis and/or chemotherapy.
1. Introduction
Worldwide, 9.6 million people are estimated to have fallen
ill with tuberculosis (TB) in 2014 [1]. Moreover, latent TB
infection (LTBI) global burden is regularly reported to
be approximately one-third of world population [1]. Since
people with LTBI are at risk for developing active TB in their
lifetime, the World Health Organization (WHO) developed
a guidance for managing LTBI, reporting evidence on testing
and treatment [2].
With TB incidence rate being considerably below 10
cases per 100,000 inhabitants over the last 10 years, Italy is
considered a low-burden country, where specific population
subgroups are affected [3].
Health care workers (HCW) are particularly at risk of
acquiring TB in all its forms [4, 5] even in countries with low
TB incidence, such as Italy.
Ameta-analysis estimated that the average annual risk for
developing TB disease was threefold higher for HCW (across
all settings) compared to the general population [5]. Also,
multidrug-resistant TB (MDR-TB) strains are associatedwith
diagnosis delay, less effective treatment, and longer contact
periods with infectious patients, increasing their potential
transmission to HCW. Consequently, HCW are up to six
times more likely to be hospitalized for MDR-TB than the
population they care for [6]. Similarly, health care students
may present a higher TB infection risk than ordinary popu-
lation [7].
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Therefore, prevention in health care settings is par-
ticularly important [1, 8, 9], and TB screening aimed at
early identification of cases is the principal step both in
countries with low and high TB incidence [10, 11]. AlsoWHO
guidelines strongly recommend a systematic testing forHCW
[2].
With regard to HCW, scientific evidence underlines pre-
employment and routine (e.g., annual, biannual etc.) screen-
ing importance, depending on risk assessment even in low
incidence countries [12]. Traditionally, tuberculin skin test
(TST) has been used for HCWTB screening; however its low
specificity among BCG-vaccinated HCW and the boosting
phenomenon of repeated tuberculin skin test may provide
false positive results, with a potential negative consequence
of unnecessary chest X rays and/or isoniazid prophylaxis.
In vitro enzyme immunoassay tests based on interferon-
gamma released (IGRAs) quantification have demonstrated
superior specificity and sensitivity compared with TST and,
moreover, only one visit is required [13–15]. In particular,
QuantiFERON-TB test in HCW has excellent utility and
accuracy especially in BCG-vaccinated populations in low
incidence countries [16], but the test is greatly expensive. In
Italy, the latest TB prevention national guidelines for HCW
launched by the Ministry of Health indicate TST as the first-
level screening test. When TST proves positive, then it may
be confirmed by the IGRAs [17].
The present study reports the results of a three-year TB
surveillance among HCW in a large Italian teaching hospital.
2. Materials and Methods
The study was carried out during the 2013–2015 period,
in the 450-bed teaching hospital “Sant’Andrea” in Rome, a
tertiary referral centre with approximately 24.000 inpatient
discharges per year. Overall, the hospital accounts for about
1,800 HCW, distributed in different working categories.
According to an internal procedure, all HCW undergo
LTBI screening both when they start working and at any time
of their working life with a frequency based on their infection
risk. To this aim, after an occupational medicine audit, HCW
accessed an outpatient clinic, where TST was performed by
two trained nurses using the standard Mantoux technique,
consisting of an intradermal injection of 0.1ml (5 IU) of
Mycobacterium tuberculosis purified proteins (PPD). The test
was read by measuring the skin reaction 72 hours after the
PPD injection. In accordance with the Italian guidelines [17]
a skin reaction ≥ 10mm was considered positive. During
the three-year study period different commercial tuberculin
products were used. During the three-year study period,
different commercial tuberculin products were used: from
January 2013 to July 2014, “PPD tuberculinmammalian” (pro-
duced by BB-NCIPD Ltd.); from August 2014 to July 2015,
“Tubertest” (produced by Sanofi Pasteur MSD); and from
August to December 2015, “PPD tuberculin mammalian”
once again.
Since May 2014, the QuantiFERON-TB Gold (QFT)
was introduced in the hospital routine TB surveillance as a
second-level screening test. The test was considered positive
when ≥0.35 IU/ml.
Data regarding all TB screening tests are routinely stored
into a password-protected database, that was anonymously
interrogated in order to carry out a descriptive study on
positive tests prevalence between January 2013 andDecember
2015. Risk factors for TB, both at and outside work, were
also analyzed and their association with TST and IGRA test
positivity was evaluated.
In order to acquire additional information on TB posi-
tivity distribution in our hospital two further databases were
interrogated. The first one was the mandatory reporting of
infectious diseases. All TB cases diagnosed in the enrolled
hospital and reported to the local health authorities were
analyzed.The second data source was the Hospital Discharge
Database (HDD),which contains anonymized administrative
and health data regarding discharged patients, which all
public and private hospitals are legally required to report.
For each patient, the main discharge diagnosis represents
the clinical condition which took up the greatest amount of
resources and involved the greatest cost for the hospital. Diag-
noses were coded using the nomenclature of the International
Classification of Diseases, 9th revision, Clinical Modification
(ICD-9-CM). We collected and examined data regarding TB
hospitalizations for the period 2013–2015, considering ICD-
9-CM codes from 0.11 to 0.18. Multiple hospital admissions
for the same case were identified by a unique key and
excluded from the analysis.
The 𝑐ℎ𝑖2 statistical test was used to evaluate the associa-
tion between independent variables. A value of 𝑝 < 0.05 was
considered significant. Adjusted odds ratios (OR) and 95%
confidence intervals (CI) were calculated for risk factors for a
positive TST andQFT using amultivariate logistic regression
model. Finally, in order to evaluate a difference in terms
of positive results between PPD tuberculin mammalian and
Tubertest, the two-sample Z-Test was used.
All statistical analyses were performed using SPSS soft-
ware version 14.
3. Results
Overall, 2,290 HCW (913 men and 1,377 women) underwent
TB screening by TST between January 2013 and December
2015. HCW median age was 44 ± 13 years and most rep-
resented professional categories were physicians and nurses,
principally belonging to medical wards. Sample distribution
by gender, TB exposure at work, vaccination status, working
area, and professional category is shown in Table 1. All
enrolled HCW were born in EU/EEA countries, except one.
None of the enrolled HCW reported TB exposure outside
work or a TB diagnosis history.
Overall, 141 (6.1%) HCW had a positive TST (Figure 1),
with a skin reaction median value of 15mm (interquartile
range ±8,5). Table 1 shows the percentage of TST pos-
itivity stratified for the above-mentioned characteristics.
The percentage of TST positive HCW was higher in 2015
(Table 2). The results stratified by TST commercial products
are reported in Table 3.
Among HCWwith a positive TST, 99 (70.2%) underwent
the second-level screening test (QFT), whereas the remaining
42 HCW were not tested by IGRA since it was introduced in
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Table 2: Number of workers tested for TB by TST, stratified by year
and results.
2013 2014 2015 Tot
Negative N. (%) 661 (94.97) 829 (94.97) 659 (91.66) 2149 (93.84)
Positive N. (%) 35 (5.03) 46 (5.26) 60 (8.34) 141 (6.16)
Tot 696 875 719 2290
2290 HCW
141 TST+
(6.1%)
16 QFT+
(16.1%) 
99 (70.2%)
83 QFT− 
(83.9%) 
42 (29.8%)QFTYes No
Figure 1: Flowchart: study population, TST, and IGRA results.
the hospital procedure only from May 2014. Out of 99 HCW
screened by IGRA, 16 (16.1%) tested positive (Figure 1); the
median QFT value was 5.5 IU/ml (interquantile range ±2.1).
The percentage of positive IGRA tests was 12.8% (5/39) and
18.3% (11/60) in HCW with positive TST in 2014 and 2015,
respectively.
Both TST and IGRA positive tests were not statistically
associated with the working area (𝑝 > 0.05). TST and
IGRA positive HCW were born in Italy and reported a
clear previous TB exposure at work in 55 cases (39%) and
11 (68.8%), respectively (Table 1). When considered as inde-
pendent variables, a TB exposure at work was significantly
associated with TST and IGRA positivity (𝑝 < 0.001 and
𝑝 < 0.05 respectively). Among HCW tested positive for TST,
90 (63,8%) reported to have been vaccinated for a Bacille
Calmette-Gue´rin (BCG), of which 4 were confirmed by IGRA
(Table 1). When considered as independent variables, to be
vaccinated was associated with TST positivity (𝑝 < 0.05),
but not with IGRA positivity (𝑝 > 0.05). The multivariate
regression model showed that the statistically significant risk
factors for a positive TST were a TB exposure at work and to
be vaccinated for BCG; on the contrary, to be vaccinated was
a protective factor for a positive IGRA (Table 1).
Comparing the TST positivity in 2015 to those in 2013 and
2014 (Table 2), the differences were statistically significant
(𝑝 < 0.05). The difference in terms of positive results be-
tween the two commercially available tuberculin skin tests
used (PPD tuberculin mammalian and Tubertest) was not
statistically significant (𝑝 < 0.05). Moreover, also the rates of
positive IGRA tests increased in 2015, although this difference
was not statistically significant (𝑝 > 0.05). Therefore, the
increased TST positivity in 2015 was considered genuine and
not due to the test used.
The hospital infectious disease notification database was
also consulted to verify a possible increase in TB cases among
patients or workers, but the number of reported TB cases
decreased in 2015 (Table 4). The same evidence was drawn
from the HDD analysis, as the number of cases with primary
diagnosis of TB decreased from 70 in 2014 to 38 in 2015 and
the same was observed for the secondary diagnosis of TB that
also decreased from 17 in 2014 to 11 in 2015.
4. Discussion
The present study reports the results of a two-step TB
screening system carried out in HCW of an Italian teaching
hospital. It shows a rate of TB infections at three years with
TST and at twenty months with IGRA of 6.1% and 1.58%,
respectively.
The annual TST positivity prevalence ranged between
5.03% and 8.34%. These data are higher if compared to
the results of an extensive review showing that median
annual estimates of latent TB in HCW are expected to
range from 3.8% to 6.9% and 8.4% in low, intermediate,
and high incidence country, respectively [5]. However, other
studies have documented an annual TST conversion rate
ranging from 1% up to 10% among exposed HCW [18–21].
It should also be noted that in all these studies authors
reported the incidence, defined as tuberculin conversion
after a documented negative-baseline TST. Differently, in our
hospital, we documented the results of a single test; therefore,
no incidence was evaluable.
A study conducted in three Norwegian hospitals showed
that, out of 387 HCW investigated, 55.3% were considered
positive at TST, of which 4.7% were confirmed by IGRA.
The percentage of TST positive was greatly higher than in
our experience and, on the contrary, the percentage of IGRA
positive seems lower than our results (16.1%); however, it
should be noted that the authors considered the TST positive
when the skin reactionwas≥ 6mm [22], whereas in our study
the cut off was 10mm.
Our TST results were in line with another two-step TB
screening in Italy that reported a 6.7% TST positive rate,
although the second step IGRA positive rate was 25% [23].
Our study demonstrated that, although there is an asso-
ciation between the risks of a positive TST or IGRA with a
working exposure, this risk was not associable with working
in high-risk areas; as previously described, some authors
found an association with working in wards, as emergency
department, where undiagnosed patients are seen [24].
Also the professional category was not associated with
a higher risk of TST of IGRA positivity, in our study. The
administrative staff showed the highest percentage of positive
TST (9,5%), but this data seems unreliable, since the number
of screened workers is not representative of the whole area;
moreover, none of TST positive administrative staff was
confirmed at IGRA. In any case, it should be noted that an
increased risk of IGRA positivity was also reported in the
BioMed Research International 5
Table 3: Number of workers tested for TB by TST and IGRA, stratified by TST test.
Period TST used % TST positive (𝑛/𝑁) % IGRA positive (𝑛/𝑁)
January 2013–July 2014 PPD tuberculin mammalian 5.3 (66/1250) —
August–December 2014 Tubertest 4.6 (15/321) 12.8% (5/39)∗
January–July 2015 Tubertest 7.3% (33/450) 18.1% (6/33)
August–December 2015 PPD tuberculin mammalian 10.4% (27/269) 18.5% (5/27)
∗This data refers to the period of May–December 2014.
Table 4: Number of TB reported cases, in 2013–2015.
2013 2014 2015
TB notifications 32 22 16
TB primary diagnosis (HDD) 57 70 38
TB secondary diagnosis (HDD) 17 17 11
administrative staff during a TB screening experience among
HCW in Germany [25].
No association was studied between country of birth
(used as proxy of country of origin) and screening positivity
since the TST positive HCW were all born in Italy. This is
not consistent with data reported at EU level: the countries
reporting most TB cases originating from other EU/EEA
were Germany and Italy [26].
We observed an increased TST positivity in HCWduring
the last year of surveillance; the analysis excluded possible
bias due to different commercial tuberculin products adopted
along the three years. Moreover TST results were consistent
with the higher positivity reached during 2015 by the IGRA
tests. In our opinion it might be possible that immigration
may had an impact on this increased prevalence as suggested
by other authors [27]. In our hospital the number of immi-
grants increased in 2015, given the existence of a referral out-
patient-clinic of infectious disease for a large immigration
centre located in the same area of the hospital. The other
data sources did not confirm an increasing trend in TB
cases, but these data do not include information regarding
infectious diseases in irregularmigrants and,moreover, those
surveillance systems are affected by under- or misreporting
[28]. In any case, no data are available from the present study
in order to confirm this hypothesis; therefore, caution must
be paid before generalizing this interpretation.
With regard to the test used for TB screening, different
limits of TST have been described, as low specificity, but on
the other hand it is easy to use and not expensive. In our
experience TST allows highly reducing the number of people
that should undergo more expensive and dangerous tests,
confirming that IGRA performed after a positive TST is more
cost effective than IGRA as first screening, especially in low
incidence countries [13].
Moreover, a large part of TST positive HCW had an
history of BCG vaccination (90/141), while the great majority
of IGRA positive (12/16) were not vaccinated; this is consis-
tent with data that underline false TST positivity in BCG-
vaccinated populations [16, 29].
Some limitations of the study include that we did not have
a negative TST baseline; therefore, no incidence is available.
Moreover, in our study, the TST was performed only to those
HCWwho started working and/or were considered at risk for
TB during the three-year period; therefore, since not all the
personnel population was tested, it is not possible to exclude
a selection bias. Finally, a precise identification of possible
exposure outside work was not possible, as the occasion of
contact with TB is difficult to identify, and since the data
analyzed were anonymized, no other risk factors such as the
socioeconomic status have been investigated.
5. Conclusions
In our experience, frequency of HCW tested positive for TB
seems low and, although different study protocols make it
hard to compare data, our results are not so far from other
experiences in low incidence countries.
The study results strongly support that, in accordance
with the Italian guidelines [17], the TST use as first step
screening may be recommended, in particular for those
HCW undergoing serial testing. At the same time, the IGRA
central role as TB second step screening in order to reduce
the number of people that should undergomore invasive tests
is confirmed, especially in those countries with high BCG
vaccination rate.
Finally, our experience did not show any significant
difference between different commercial products for TST
execution, but, since the study was a retrospective study over
a three-year follow-up period, further ad hoc studies are
necessary for confirming this data.
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